Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine Pendleton, Ajay K. Nooka, Natalia Neparidze, Terri L. Parker, Noffar Bar, Jonathan L. Kaufman, Craig C. Hofmeister, Lawrence H. Boise, Sagar Lonial, Melissa L. Kemp, Kavita M. Dhodapkar, Madhav V. Dhodapkar
Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine Pendleton, Ajay K. Nooka, Natalia Neparidze, Terri L. Parker, Noffar Bar, Jonathan L. Kaufman, Craig C. Hofmeister, Lawrence H. Boise, Sagar Lonial, Melissa L. Kemp, Kavita M. Dhodapkar, Madhav V. Dhodapkar
View: Text | PDF
Research Article Immunology Oncology

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

  • Text
  • PDF
Abstract

Preneoplastic lesions carry many of the antigenic targets found in cancer cells but often exhibit prolonged dormancy. Understanding how the host response to premalignancy is maintained and altered during malignant transformation is needed to prevent cancer. To understand the immune microenvironment in precursor monoclonal gammopathy of undetermined significance (MGUS) and myeloma, we analyzed bone marrow immune cells from 12 healthy donors and 26 patients with MGUS/myeloma by mass cytometry and concurrently profiled transcriptomes of 42,606 single immune cells from these bone marrow samples. Compared with age-matched healthy donors, memory T cells from both MGUS and myeloma patients exhibited greater terminal effector differentiation. However, memory T cells in MGUS show greater enrichment of stem-like TCF1/7hi cells. Clusters of T cells with stem-like and tissue residence genes were also found to be enriched in MGUS by single-cell transcriptome analysis. Early changes in both NK and myeloid cells were also observed in MGUS. Enrichment of stem-like T cells correlated with a distinct genomic profile of myeloid cells and levels of Dickkopf-1 in bone marrow plasma. These data describe the landscape of changes in both innate and adaptive immunity in premalignancy and suggest that attrition of the bone marrow–resident T cell compartment because of loss of stem-like cells may underlie loss of immune surveillance in myeloma.

Authors

Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie, Mahesh Shrestha, Katherine Pendleton, Ajay K. Nooka, Natalia Neparidze, Terri L. Parker, Noffar Bar, Jonathan L. Kaufman, Craig C. Hofmeister, Lawrence H. Boise, Sagar Lonial, Melissa L. Kemp, Kavita M. Dhodapkar, Madhav V. Dhodapkar

×

Figure 1

Bone marrow mononuclear cells from healthy donors (n = 7), MGUS (n = 8), and myeloma (n = 10) were characterized using single-cell mass cytometry.

Options: View larger image (or click on image) Download as PowerPoint
Bone marrow mononuclear cells from healthy donors (n = 7), MGUS (n = 8),...
(A) Central memory (CD45RO+CCR7+) CD8+ and CD4+ T cells as percentage of total memory CD8+ and CD4+ T cells. (B) CD8+ and CD4+ effector T cells (Tefs) (effector memory cells, Tems: CD45RO+CCR7–; and terminal effectors, Ttes: CD45RO–CCR7–) as percentage of total memory CD8+ and CD4+ T cells. (C) CD8+ Tems and Ttes as percentage of CD8+ Tefs. (D) CD4+ Tems and Ttes as percentage of CD4+ Tefs. (E) Median expression of TCF1 and GATA-3 transcription factors in CD8+ memory T cells. (F) Median expression of Eomes and T-bet in memory CD8+ T cells. (G) Gating strategy for defining cells that express high levels of TCF1 (TCFhi) and intermediate levels of TCF1 (TCFint) and those that do not express TCF1 transcription factor (TCF1neg). A representative dot plot from a patient with MGUS. (H) Percentage of memory CD8+ T cells that express TCF1hi or TCFint or lack TCF1 expression (TCF1neg). (I) Percentage of TCF1hi in CD8+ Tems, Tcms, and Ttes. (J) Characteristics of the TCF1hi, TCF1int, and TCF1neg CD8+ memory T cells. All bar graphs show mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts